Abstract
Rheumatoid arthritis (RA) is a chronic disabling disease where continued disease activity translates to irreversible articular damage. Seropositivity for rheumatoid factor (RF) and anticitrullinated protein antibody (ACPA) are markers of poorer prognosis; with increased disease activity, radiographic progression and even mortality.1 However, other than ACPA, no other biomarker has emerged for clinical use in the last 10 years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have